What's Happening?
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center has found that biofield therapy (BT), a non-invasive treatment, can significantly slow the growth and spread of pancreatic cancer. Funded by the Emerald Gate Charitable
Trust, the study demonstrated that BT reduced cancer cell proliferation and metastasis, particularly to the liver, by more than 50% in mouse models. The research, published in Cancer Medicine, highlights BT's potential as a complementary treatment for pancreatic cancer, one of the most lethal and treatment-resistant cancers. The study also noted changes in mitochondrial structure and cell membrane potential, along with the downregulation of cancer-related genes. The findings suggest a real biological impact from BT, warranting further investigation into its mechanisms and potential role in cancer care.
Why It's Important?
Pancreatic cancer is one of the deadliest forms of cancer, with a survival rate of 10% or less over 12 months for those with metastatic disease. The study's findings offer hope for new treatment strategies that could complement existing therapies. If BT's efficacy is confirmed in human trials, it could lead to less invasive treatment options, reducing the need for aggressive chemotherapy and its associated side effects. This development could significantly impact patient outcomes and quality of life, offering a new avenue for integrative cancer care.
What's Next?
The research team plans to continue exploring the mechanisms behind BT's effects, including potential electromagnetic field interactions and immune modulation. These efforts aim to pave the way for human clinical trials, which could validate BT's effectiveness in cancer treatment. If successful, BT could be integrated into standard cancer care protocols, potentially transforming treatment approaches for pancreatic and other cancers.
